The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack

Erin G. Doty[1], Paula M. Hauck[1], John H. Krege[1], Mika Komori[1], Ann M. Hake[1,2], Yan Dong[1], Richard B. Lipton[3]

[1] Eli Lilly and Company, Indianapolis, IN, USA.

[2] Indiana University School of Medicine, Indianapolis, IN, USA.

[3] Albert Einstein School of Medicine, The Bronx, NY, USA.

CNS Drugs

Short title: TEAEs and efficacy of LTN

Key words: lasmiditan, migraine, treatment-emergent adverse events, pain freedom, efficacy, efficacy-TEAE association

Corresponding author:

Erin G. Doty, MD

Lilly Technology Center South, Indianapolis IN 46221 U.S.A.

doty_erin_gautier@lilly.com

+1 (317)517-4018 (mobile)

Supplemental Table 1. Additional demographic breakdown by country

	Placebo (N=1976)	L50 mg (N=742)	L100 mg (N=1958)	L200 mg (N=1926)
Country*				
Austria n (%)	3 (0.2)	0 (0.0)	5 (0.3)	3 (0.2)
Belgium n (%)	9 (0.5)	0 (0.0)	9 (0.5)	10 (0.5)
Switzerland n (%)	7 (0.4)	0 (0.0)	5 (0.3)	7 (0.4)
China n (%)	47 (2.4)	0 (0.0)	45 (2.3)	44 (2.3)
Czech Republic n (%)	31 (1.6)	0 (0.0)	33 (1.7)	32 (1.7)
Germany n (%)	155 (7.8)	68 (9.2)	153 (7.8)	154 (8.0)
Denmark n (%)	11 (0.6)	0 (0.0)	9 (0.5)	10 (0.5)
Spain n (%)	22 (1.1)	0 (0.0)	18 (0.9)	21 (1.1)
France n (%)	8 (0.4)	0 (0.0)	7 (0.4)	7 (0.4)
United Kingdom n (%)	209 (10.6)	44 (5.9)	207 (10.6)	204 (10.6)
Hungary n (%)	5 (0.3)	0 (0.0)	6 (0.3)	6 (0.3)
India n (%)	13 (0.7)	0 (0.0)	12 (0.6)	14 (0.7)
Italy n (%)	8 (0.4)	0 (0.0)	7 (0.4)	7 (0.4)
Japan n (%)	214 (10.8)	88 (11.9)	208 (10.6)	182 (9.4)
Mexico n (%)	34 (1.7)	0 (0.0)	29 (1.5)	32 (1.7)
Netherlands n (%)	3 (0.2)	0 (0.0)	3 (0.2)	4 (0.2)
Russian Federation n (%)	13 (0.7)	0 (0.0)	13 (0.7)	12 (0.6)
United States n (%)	1184 (59.9)	542 (73.0)	1189 (60.7)	1177 (61.1)

* The denominator = the number of participants with non-missing data and therefore may be slightly different than the N shown.

Notes: Pooled data from SAMURAI, SPARTAN, MONONOFU, and the first treated attack from CENTURION were used in the analysis.

Abbreviations: L = lasmiditan; N = number of participants in the analysis population; n = number of subjects within each specific category

Supplemental Table 2. Proportions of participants experiencing CTEAEs by 48 hours based on 2-hour pain outcome

	Placebo N=1745			L50 mg N=673			L100 mg N=1719			L200 mg N=1698		
Participants with	N'	n (%)	Odds Ratio (95% CI) vs. M/S	N'	n (%)	Odds Ratio (95% CI) vs. M/S	N'	n (%)	Odds Ratio (95% CI) vs. M/S	N'	n (%)	Odds Ratio (95% CI) vs. M/S
≥1 CTEAE												
M/S	782	71 (9.1)		204	41 (20.1)		417	109 (26.1)		404	116 (28.7)	
IMP	496	59 (11.9)	1.3 (0.9, 1.9)	203	48 (23.6)	1.2 (0.7, 1.9)	574	226 (39.4)	1.7 (1.2, 2.2)***	473	233 (49.3)	2.2 (1.7, 3.0)***
PF	270	21 (7.8)	0.9 (0.5, 1.5)	184	51 (27.7)	1.6 (1.0, 2.5)	498	205 (41.2)	2.0 (1.5, 2.7)***	575	277 (48.2)	2.4 (1.8, 3.1)***
Dizziness												
M/S	782	29 (3.7)		204	15 (7.4)		417	50 (12.0)		404	63 (15.6)	
IMP	496	21 (4.2)	1.1 (0.6, 2.0)	203	24 (11.8)	1.6 (0.8, 3.3)	574	144 (25.1)	2.2 (1.6, 3.2)***	473	140 (29.6)	2.1 (1.5, 2.9)***
PF	270	5 (1.9)	0.6 (0.2, 1.5)	184	29 (15.8)	2.4 (1.2, 4.5)**	498	126 (25.3)	2.4 (1.7, 3.5)***	575	149 (25.9)	1.8 (1.3, 2.6)***
Somnolence												
M/S	782	11 (1.4)		204	10 (4.9)		417	19 (4.6)		404	15 (3.7)	
IMP	496	19 (3.8)	2.7 (1.3, 5.7)**	203	11 (5.4)	1.0 (0.4, 2.5)	574	41 (7.1)	1.3 (0.7, 2.3)	473	40 (8.5)	1.9 (1.0, 3.6)*
PF	270	10 (3.7)	2.5 (1.0, 6.1)*	184	15 (8.2)	1.8 (0.8, 4.0)	498	43 (8.6)	1.8 (1.0, 3.2)*	575	67 (11.7)	3.3 (1.8, 5.9)***
Paresthesia												
M/S	782	11 (1.4)		204	3 (1.5)		417	19 (4.6)		404	26 (6.4)	
IMP	496	12 (2.4)	1.8 (0.8, 4.2)	203	6 (3.0)	2.1 (0.5, 8.8)	574	39 (6.8)	1.6 (0.9, 2.9)	473	52 (11.0)	1.9 (1.2, 3.1)*
PF	270	4 (1.5)	1.2 (0.4, 4.0)	184	7 (3.8)	2.6 (0.7, 10.2)	498	34 (6.8)	1.7 (0.9, 3.0)	575	58 (10.1)	1.8 (1.1, 2.9)*
Nausea												
M/S	782	22 (2.8)		204	11 (5.4)		417	27 (6.5)		404	20 (5.0)	
IMP	496	11 (2.2)	0.7 (0.4, 1.5)	203	5 (2.5)	0.4 (0.1, 1.2)	574	17 (3.0)	0.4 (0.2, 0.8)**	473	28 (5.9)	1.1 (0.6, 1.9)
PF	270	3 (1.1)	0.4 (0.1, 1.6)	184	4 (2.2)	0.4 (0.1, 1.2)	498	19 (3.8)	0.6 (0.3, 1.1)	575	33 (5.7)	1.2 (0.7, 2.2)
Fatigue												
M/S	782	7 (0.9)		204	6 (2.9)		417	17 (4.1)		404	16 (4.0)	
IMP	496	3 (0.6)	0.7 (0.2, 2.6)	203	5 (2.5)	0.9 (0.3, 2.9)	574	32 (5.6)	1.4 (0.8, 2.6)	473	29 (6.1)	1.5 (0.8, 2.9)
PF	270	0 (0.0)	0.0 (-, -)	184	5 (2.7)	0.9 (0.3, 3.1)	498	26 (5.2)	1.4 (0.7, 2.6)	575	41 (7.1)	2.0 (1.1, 3.7)*

* p<0.05, ** p<0.01, *** p<0.001

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; IMP = improved to mild; L = lasmiditan; M/S = continued moderate/severe; N = number of participants in the analysis population; N' = number of participants experiencing the pain category; n = number of participants experiencing the pain category and treatment-emergent adverse event; PF = pain freedom

Supplemental Table 3. Proportion of participants experiencing CTEAEs by 48 hours based on 2-hour disability freedom

	Placebo N=1760			L50 mg N=679			L100 mg N=1742			L200 mg N=1708		
Participants with	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)
≥1 CTEAE												
DF	333	24 (7.2)	0.7 (0.5, 1.2)	205	46 (22.4)	1.0 (0.7, 1.5)	493	161 (32.7)	0.9 (0.7, 1.2)	511	217 (42.5)	1.1 (0.9, 1.4)
No DF	1259	129 (10.2)		412	96 (23.3)		1076	407 (37.8)		1002	433 (43.2)	
Dizziness												
DF	333	6 (1.8)	0.5 (0.2, 1.2)	205	27 (13.2)	1.5 (0.9, 2.4)	493	96 (19.5)	1.0 (0.7, 1.3)	511	116 (22.7)	1.0 (0.8, 1.3)
No DF	1259	50 (4.0)		412	41 (10.0)		1076	237 (22.0)		1002	250 (25.0)	
Somnolence												
DF	333	10 (3.0)	1.1 (0.5, 2.4)	205	14 (6.8)	1.2 (0.6, 2.4)	493	34 (6.9)	1.1 (0.7, 1.7)	511	53 (10.4)	1.7 (1.1, 2.4)*
No DF	1259	30 (2.4)		412	24 (5.8)		1076	74 (6.9)		1002	74 (7.4)	
Paresthesia												
DF	333	4 (1.2)	0.7 (0.2, 1.9)	205	7 (3.4)	1.4 (0.5, 3.7)	493	26 (5.3)	0.8 (0.5, 1.3)	511	53 (10.4)	1.3 (0.9, 1.9)
No DF	1259	23 (1.8)		412	10 (2.4)		1076	71 (6.6)		1002	88 (8.8)	
Nausea												
DF	333	3 (0.9)	0.4 (0.1, 1.3)	205	3 (1.5)	0.3 (0.1, 1.2)	493	8 (1.6)	0.3 (0.2, 0.7)**	511	24 (4.7)	1.0 (0.6, 1.6)
No DF	1259	34 (2.7)		412	17 (4.1)		1076	59 (5.5)		1002	59 (5.9)	
Fatigue												
DF	333	0 (0.0)	0.0 (-, -)	205	3 (1.5)	0.4 (0.1, 1.6)	493	18 (3.7)	0.7 (0.4, 1.2)	511	31 (6.1)	1.3 (0.8, 2.1)
No DF	1259	10 (0.8)		412	13 (3.2)		1076	62 (5.8)		1002	55 (5.5)	

* p<0.05, ** p<0.01

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; DF = disability freedom; L = lasmiditan; N = number of participants in the analysis population; N' = number of participants experiencing the disability category; n = number of participants experiencing the disability category and CTEAE

Supplemental Table 4. Proportion of participants experiencing CTEAEs by 48 hours based on 2-hour improved PGIC

	Placebo N=1829			L50 mg N=685			L100 mg N=1800			L200 mg N=1766		
Participants with	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)
≥1 CTEAE												
MB/VMB	391	38 (9.7)	1.1 (0.7, 1.6)	250	58 (23.2)	1.1 (0.7, 1.6)	662	240 (36.3)	1.1 (0.9, 1.3)	667	304 (45.6)	1.3 (1.0, 1.6)*
Other	1219	115 (9.4)		372	84 (22.6)		922	332 (36.0)		863	353 (40.9)	
Dizziness												
MB/VMB	391	11 (2.8)	0.8 (0.4, 1.6)	250	31 (12.4)	1.3 (0.8, 2.2)	662	141 (21.3)	1.0 (0.8, 1.3)	667	170 (25.5)	1.1 (0.9, 1.4)
Other	1219	45 (3.7)		372	37 (9.9)		922	192 (20.8)		863	201 (23.3)	
Somnolence												
MB/VMB	391	18 (4.6)	2.4 (1.2, 4.5)**	250	17 (6.8)	1.2 (0.6, 2.4)	662	51 (7.7)	1.1 (0.8, 1.7)	667	61 (9.1)	1.1 (0.8, 1.7)
Other	1219	23 (1.9)		372	21 (5.6)		922	61 (6.6)		863	67 (7.8)	
Paresthesia												
MB/VMB	391	9 (2.3)	1.7 (0.7, 3.8)	250	8 (3.2)	1.3 (0.5, 3.4)	662	40 (6.0)	1.1 (0.7, 1.6)	667	71 (10.6)	1.5 (1.1, 2.1)*
Other	1219	18 (1.5)		372	9 (2.4)		922	57 (6.2)		863	71 (8.2)	
Nausea												
MB/VMB	391	6 (1.5)	0.7 (0.3, 1.8)	250	3 (1.2)	0.3 (0.1, 0.9)*	662	17 (2.6)	0.5 (0.3, 0.9)*	667	25 (3.7)	0.6 (0.4, 0.9)*
Other	1219	30 (2.5)		372	17 (4.6)		922	50 (5.4)		863	60 (7.0)	
Fatigue												
MB/VMB	391	0 (0.0)	0.0 (-, -)	250	5 (2.0)	0.7 (0.2, 1.9)	662	33 (5.0)	1.1 (0.7, 1.7)	667	42 (6.3)	1.3 (0.8, 2.0)
Other	1219	11 (0.9)		372	11 (3.0)		922	47 (5.1)		863	47 (5.4)	

* p<0.05, ** p<0.01

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; L = lasmiditan; MB/VMB = much better/very much better; N = number of participants in the analysis population; N' = number of participants experiencing the PGIC category; n = number of participants experiencing the PGIC category and CTEAE; PGIC = patient global impression of change

Supplemental Table 5. Pain freedom in participants with a CTEAE or no CTEAE

	Placebo N=1745			L50 mg N=673			L100 mg N=1719			L200 mg N=1698		
Participants with	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)
≥1 CTEAE												
No	1581	249 (15.7)	0.8 (0.5, 1.3)	523	133 (25.4)	1.5 (1.0, 2.2)	1111	293 (26.4)	1.5 (1.2, 1.8)**	988	298 (30.2)	1.5 (1.2, 1.9)***
Yes	164	21 (12.8)		150	51 (34.0)		608	205 (33.7)		710	277 (39.0)	
before 2h	92	13 (14.1)	0.7 (0.2, 2.3)	79	30 (38.0)	2.0 (0.7, 5.6)	445	154 (34.6)	1.2 (0.7, 2.2)	523	225 (43.0)	3.2 (1.8, 5.8)***
after 2h	43	5 (11.6)		24	6 (25.0)		67	19 (28.4)		84	16 (19.0)	
Dizziness												
No	1686	265 (15.7)	0.5 (0.2, 1.4)	600	155 (25.8)	1.9 (1.2, 3.2)*	1364	372 (27.3)	1.5 (1.2, 1.9)**	1297	426 (32.8)	1.2 (0.9, 1.5)
Yes	59	5 (8.5)		73	29 (39.7)		355	126 (35.5)		401	149 (37.2)	
before 2h	33	2 (6.1)	0.6 (0.1, 5.6)	33	15 (45.5)	1.8 (0.5, 6.7)	271	97 (35.8)	1.6 (0.7, 3.9)	300	124 (41.3)	3.2 (1.3, 7.5)**
after 2h	14	1 (7.1)		14	5 (35.7)		30	8 (26.7)		43	7 (16.3)	
Somnolence												
No	1704	260 (15.3)	1.5 (0.7, 3.2)	633	169 (26.7)	1.6 (0.8, 3.2)	1601	455 (28.4)	1.5 (1.0, 2.2)	1563	508 (32.5)	2.0 (1.4, 2.9)***
Yes	41	10 (24.4)		40	15 (37.5)		118	43 (36.4)		135	67 (49.6)	
before 2h	27	6 (22.2)	0.3 (0.0, 3.0)	26	10 (38.5)	3.1 (0.3, 32.8)	85	32 (37.6)	1.2 (0.4, 4.0)	101	51 (50.5)	2.6 (1.0, 7.2)
after 2h	8	2 (25.0)		6	1 (16.7)		17	5 (29.4)		23	8 (34.8)	
Paresthesia												
No	1714	266 (15.5)	0.9 (0.3, 2.7)	656	177 (27.0)	1.6 (0.6, 4.3)	1616	464 (28.7)	1.2 (0.8, 1.9)	1550	517 (33.4)	1.3 (0.9, 1.9)
Yes	31	4 (12.9)		17	7 (41.2)		103	34 (33.0)		148	58 (39.2)	
before 2h	16	2 (12.5)	0.5 (0.1, 3.6)	8	2 (25.0)	0.4 (0.0, 10.0)	73	26 (35.6)	1.9 (0.4, 9.7)	115	50 (43.5)	5.8 (1.0, 34.5)*
after 2h	11	2 (18.2)		2	1 (50.0)		11	2 (18.2)		13	2 (15.4)	
Nausea												
No	1705	267 (15.7)	0.5 (0.1, 1.7)	652	180 (27.6)	0.6 (0.2, 1.8)	1643	479 (29.2)	0.9 (0.5, 1.5)	1594	542 (34.0)	1.2 (0.7, 1.8)
Yes	40	3 (7.5)		21	4 (19.0)		76	19 (25.0)		104	33 (31.7)	
before 2h	20	3 (15.0)	NA	10	3 (30.0)	0.6 (0.0, 13.6)	50	15 (30.0)	3.0 (0.5, 17.4)	70	24 (34.3)	2.5 (0.7, 8.9)
after 2h	15	0 (0.0)		5	1 (20.0)		12	2 (16.7)		20	4 (20.0)	
Fatigue												
No	1731	270 (15.6)	0.0 (-, -)	654	179 (27.4)	1.0 (0.3, 3.0)	1633	472 (28.9)	1.1 (0.7, 1.8)	1603	534 (33.3)	1.6 (1.0, 2.4)*
Yes	14	0 (0.0)		19	5 (26.3)		86	26 (30.2)		95	41 (43.2)	
before 2h	6	0 (0.0)	NA	9	2 (22.2)	1.3 (0.1, 26.6)	56	16 (28.6)	1.1 (0.2, 4.8)	63	27 (42.9)	0.9 (0.2, 3.3)
after 2h	5	0 (0.0)		3	1 (33.3)		12	4 (33.3)		13	6 (46.2)	

* p<0.05, ** p<0.01, *** p<0.001

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N= number of participants in the treatment group; N' = number of participants experiencing the TEAE category; n = number of participants experiencing the TEAE category and pain freedom; NA = not applicable

Supplemental Table 6. Disability freedom in participants with a CTEAE or no CTEAE

	Placebo N=1760			L50 mg N=679			L100 mg N=1742			L200 mg N=1708		
Participants with	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)
≥1 CTEAE												
No	1591	309 (19.4%)	0.7 (0.5, 1.2)	529	159 (30.1%)	1.0 (0.7, 1.5)	1125	332 (29.5%)	0.9 (0.7, 1.2)	992	294 (29.6%)	1.1 (0.9, 1.4)
Yes	169	24 (14.2%)		150	46 (30.7%)		617	161 (26.1%)		716	217 (30.3%)	
before 2h	96	14 (14.6%)	0.6 (0.2, 1.9)	79	26 (32.9%)	1.9 (0.6, 5.7)	449	114 (25.4%)	0.7 (0.4, 1.2)	528	164 (31.1%)	1.9 (1.0, 3.4)*
after 2h	45	6 (13.3%)		24	5 (20.8%)		70	21 (30.0%)		84	17 (20.2%)	
Dizziness												
No	1698	327 (19.3%)	0.5 (0.2, 1.2)	606	178 (29.4%)	1.5 (0.9, 2.4)	1380	397 (28.8%)	1.0 (0.7, 1.3)	1306	395 (30.2%)	1.0 (0.8, 1.3)
Yes	62	6 (9.7%)		73	27 (37.0%)		362	96 (26.5%)		402	116 (28.9%)	
before 2h	35	2 (5.7%)	0.2 (0.0, 2.0)	33	17 (51.5%)	4.2 (0.9, 18.6)	274	68 (24.8%)	0.7 (0.3, 1.7)	301	90 (29.9%)	1.4 (0.6, 3.0)
after 2h	15	2 (13.3%)		14	3 (21.4%)		31	10 (32.3%)		43	10 (23.3%)	
Somnolence												
No	1718	323 (18.8%)	1.1 (0.5, 2.4)	639	191 (29.9%)	1.2 (0.6, 2.4)	1623	459 (28.3%)	1.1 (0.7, 1.7)	1571	458 (29.2%)	1.7 (1.1, 2.4)*
Yes	42	10 (23.8%)		40	14 (35.0%)		119	34 (28.6%)		137	53 (38.7%)	
before 2h	28	7 (25.0%)	0.6 (0.0, 13.6)	26	9 (34.6%)	2.6 (0.2, 27.1)	84	24 (28.6%)	0.8 (0.3, 2.5)	102	38 (37.3%)	1.4 (0.5, 3.8)
after 2h	8	1 (12.5%)		6	1 (16.7%)		20	6 (30.0%)		23	8 (34.8%)	
Paresthesia												
No	1729	329 (19.0%)	0.7 (0.2, 1.9)	662	198 (29.9%)	1.4 (0.5, 3.7)	1639	467 (28.5%)	0.8 (0.5, 1.3)	1556	458 (29.4%)	1.3 (0.9, 1.9)
Yes	31	4 (12.9%)		17	7 (41.2%)		103	26 (25.2%)		152	53 (34.9%)	
before 2h	16	2 (12.5%)	0.5 (0.1, 3.6)	8	1 (12.5%)	0.2 (0.0, 5.5)	73	19 (26.0%)	0.8 (0.1, 4.1)	119	46 (38.7%)	5.3 (0.9, 32.4)
after 2h	11	2 (18.2%)		2	1 (50.0%)		11	3 (27.3%)		13	2 (15.4%)	
Nausea												
No	1719	330 (19.2%)	0.4 (0.1, 1.3)	658	202 (30.7%)	0.3 (0.1, 1.2)	1665	485 (29.1%)	0.3 (0.2, 0.7)**	1604	487 (30.4%)	1.0 (0.6, 1.6)
Yes	41	3 (7.3%)		21	3 (14.3%)		77	8 (10.4%)		104	24 (23.1%)	
before 2h	20	2 (10.0%)	NA	10	2 (20.0%)	0.3 (0.0, 8.2)	50	5 (10.0%)	0.6 (0.1, 3.5)	71	14 (19.7%)	1.4 (0.3, 6.1)
after 2h	16	0 (0.0%)		5	1 (20.0%)		12	2 (16.7%)		19	3 (15.8%)	
Fatigue												
No	1746	333 (19.1%)	0.0 (-, -)	660	202 (30.6%)	0.4 (0.1, 1.6)	1655	475 (28.7%)	0.7 (0.4, 1.2)	1615	480 (29.7%)	1.3 (0.8, 2.1)
Yes	14	0 (0.0%)		19	3 (15.8%)		87	18 (20.7%)		93	31 (33.3%)	
before 2h	7	0 (0.0%)	NA	9	0 (0.0%)	0.0 (-, -)	57	11 (19.3%)	0.9 (0.2, 4.6)	62	18 (29.0%)	1.8 (0.3, 9.9)
after 2h	5	0 (0.0%)		3	1 (33.3%)		12	3 (25.0%)		12	2 (16.7%)	

* p<0.05, ** p<0.01, *** p<0.001

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N = number of participants in each treatment group; N' = number of participants experiencing the CTEAE category; n = number of participants experiencing the CTEAE category and disability freedom

Supplemental Table 7. Improved PGIC in participants with a CTEAE or no CTEAE

	Placebo N=1829			L50 mg N=685			L100 mg N=1800			L200 mg N=1766		
Participants with	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)	N'	n (%)	Odds Ratio (95% CI)
≥1 CTEAE												
No	1652	353 (21.4%)	1.1 (0.7, 1.6)	535	192 (35.9%)	1.1 (0.7, 1.6)	1172	422 (36.0%)	1.1 (0.9, 1.3)	1031	363 (35.2%)	1.3 (1.0, 1.6)*
Yes	177	38 (21.5%)		150	58 (38.7%)		628	240 (38.2%)		735	304 (41.4%)	
before 2h	99	26 (26.3%)	1.7 (0.6, 4.7)	79	29 (36.7%)	1.2 (0.5, 3.3)	454	182 (40.1%)	1.9 (1.1, 3.5)*	542	242 (44.6%)	2.4 (1.4, 4.1)**
after 2h	48	6 (12.5%)		24	8 (33.3%)		72	17 (23.6%)		88	22 (25.0%)	
Dizziness												
No	1765	380 (21.5%)	0.8 (0.4, 1.6)	612	219 (35.8%)	1.3 (0.8, 2.2)	1436	521 (36.3%)	1.0 (0.8, 1.3)	1353	497 (36.7%)	1.1 (0.9, 1.4)
Yes	64	11 (17.2%)		73	31 (42.5%)		364	141 (38.7%)		413	170 (41.2%)	
before 2h	36	6 (16.7%)	1.0 (0.2, 5.3)	33	15 (45.5%)	0.9 (0.2, 3.6)	275	106 (38.5%)	1.6 (0.7, 3.7)	309	131 (42.4%)	1.2 (0.6, 2.3)
after 2h	16	2 (12.5%)		14	6 (42.9%)		32	9 (28.1%)		45	16 (35.6%)	
Somnolence												
No	1785	373 (20.9%)	2.4 (1.2, 4.5)**	645	233 (36.1%)	1.2 (0.6, 2.4)	1677	611 (36.4%)	1.1 (0.8, 1.7)	1626	606 (37.3%)	1.1 (0.8, 1.7)
Yes	44	18 (40.9%)		40	17 (42.5%)		123	51 (41.5%)		140	61 (43.6%)	
before 2h	29	14 (48.3%)	1.6 (0.3, 9.6)	26	10 (38.5%)	1.2 (0.2, 8.1)	87	40 (46.0%)	1.7 (0.6, 5.1)	103	48 (46.6%)	1.7 (0.6, 4.6)
after 2h	9	2 (22.2%)		6	2 (33.3%)		20	6 (30.0%)		24	9 (37.5%)	
Paresthesia												
No	1798	382 (21.2%)	1.7 (0.7, 3.8)	668	242 (36.2%)	1.3 (0.5, 3.4)	1695	622 (36.7%)	1.1 (0.7, 1.6)	1611	596 (37.0%)	1.5 (1.1, 2.1)*
Yes	31	9 (29.0%)		17	8 (47.1%)		105	40 (38.1%)		155	71 (45.8%)	
before 2h	16	6 (37.5%)	2.3 (0.2, 25.8)	8	3 (37.5%)	NA	74	32 (43.2%)	3.4 (0.6, 19.3)	122	65 (53.3%)	10.5 (1.7, 67.2)**
after 2h	11	2 (18.2%)		2	0 (0.0%)		12	2 (16.7%)		13	2 (15.4%)	
Nausea												
No	1787	385 (21.5%)	0.7 (0.3, 1.8)	664	247 (37.2%)	0.3 (0.1, 0.9)*	1720	645 (37.5%)	0.5 (0.3, 0.9)*	1659	642 (38.7%)	0.6 (0.4, 0.9)*
Yes	42	6 (14.3%)		21	3 (14.3%)		80	17 (21.3%)		107	25 (23.4%)	
before 2h	20	5 (25.0%)	NA*	10	2 (20.0%)	NA	51	8 (15.7%)	0.5 (0.1, 2.3)	73	18 (24.7%)	2.3 (0.6, 9.3)
after 2h	16	0 (0.0%)		5	0 (0.0%)		12	4 (33.3%)		20	3 (15.0%)	
Fatigue												
No	1812	391 (21.6%)	0.0 (-, -)	666	245 (36.8%)	0.7 (0.2, 1.9)	1711	629 (36.8%)	1.1 (0.7, 1.7)	1665	625 (37.5%)	1.3 (0.8, 2.0)
Yes	17	0 (0.0%)		19	5 (26.3%)		89	33 (37.1%)		101	42 (41.6%)	
before 2h	8	0 (0.0%)	NA	9	2 (22.2%)	1.3 (0.1, 26.6)	57	21 (36.8%)	1.2 (0.3, 5.1)	67	26 (38.8%)	1.7 (0.4, 6.6)
after 2h	6	0 (0.0%)		3	1 (33.3%)		13	4 (30.8%)		15	4 (26.7%)	

* p<0.05, ** p<0.01, *** p<0.001

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N = number of participants in each treatment group; N' = number of participants experiencing the CTEAE category; n = number of participants experiencing the CTEAE category and PGIC; PGIC = patient global impression of change